Development of a recombinant oncolytic poliovirus type 3 strain with altered cell tropism

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL

Bulletin of Russian State Medical University Pub Date : 2022-04-01 DOI:10.24075/brsmu.2022.023

Вестник Ргму, VESTNIKRGMU.RU Hamad, A. Soboleva, P. Vorobyev, K. Vasilenko, P. Chumakov, A. Lipatova, A. Lipatova

引用次数: 1

Abstract

Diffuse gliomas are incurable, prevalent, and aggressive central nervous system tumors. Therefore, the development of selective oncolytic viral strains for malignant neoplasms is highly relevant. This study aimed to create an oncolytic virus based on a vaccine strain of poliovirus type 3 with natural antitumor activity. To achieve this goal, we replaced the internal ribosome entry site (IRES) of poliovirus with the corresponding fragment of human rhinovirus 30. The resulting recombinant oncolytic strain RVP3 retained the serotype of poliovirus type 3, as confirmed by virus neutralization micro-test with specific antiserum. In addition, the oncolytic efficacy of RVP3 was assessed in vitro on a broad panel of cell cultures. According to the results, RVP3 has changed its tropism, losing the ability to replicate in conditionally normal cell lines of embryonic astrocytes and embryonic fibroblasts while retaining the ability to replicate in tumor cells.

查看原文本刊更多论文

细胞嗜性改变的重组溶瘤性脊髓灰质炎病毒3型毒株的研制

弥漫性胶质瘤是不可治愈的、普遍存在的、侵袭性的中枢神经系统肿瘤。因此，开发用于恶性肿瘤的选择性溶瘤病毒株是高度相关的。本研究旨在以具有天然抗肿瘤活性的3型脊髓灰质炎病毒疫苗株为基础，创造一种溶瘤病毒。为了实现这一目标，我们用人类鼻病毒30的相应片段取代了脊髓灰质炎病毒的内部核糖体进入位点（IRES）。所得到的重组溶瘤菌株RVP3保留了脊髓灰质炎病毒3型的血清型，如用特异性抗血清进行的病毒中和微试验所证实的。此外，在广泛的细胞培养物上对RVP3的溶瘤功效进行了体外评估。根据结果，RVP3改变了其向性，失去了在胚胎星形胶质细胞和胚胎成纤维细胞的条件正常细胞系中复制的能力，同时保留了在肿瘤细胞中复制的功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin of Russian State Medical University MEDICINE, GENERAL & INTERNAL-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Bulletin of Russian State Medical University (Bulletin of RSMU, ISSN Print 2500–1094, ISSN Online 2542–1204) is a peer-reviewed medical journal of Pirogov Russian National Research Medical University (Moscow, Russia). The original language of the journal is Russian (Vestnik Rossiyskogo Gosudarstvennogo Meditsinskogo Universiteta, Vestnik RGMU, ISSN Print 2070–7320, ISSN Online 2070–7339). Founded in 1994, it is issued once every two months publishing articles on clinical medicine and medical and biological sciences, first of all oncology, neurobiology, allergy and immunology, medical genetics, medical microbiology and infectious diseases. Every issue is thematic. Deadlines for manuscript submission are announced in advance. The number of publications on topics in spite of the issue topic is limited. The journal accepts only original articles submitted by their authors, including articles that present methods and techniques, clinical cases and opinions. Authors must guarantee that their work has not been previously published elsewhere in whole or in part and in other languages and is not under consideration by another scientific journal. The journal publishes only one review per issue; the review is ordered by the editors.